Abstract
Kramer et al. examine the reasons put forth by investigators for excluding a sham condition in trials of neuromodulation therapies for individuals with spinal cord injury. They conclude that current dogma does not justify this design, and emphasize the need for future trials to include appropriate controls.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have